AU2021361043A1 - Tricyclic ligands for degradation of ikzf2 or ikzf4 - Google Patents
Tricyclic ligands for degradation of ikzf2 or ikzf4 Download PDFInfo
- Publication number
- AU2021361043A1 AU2021361043A1 AU2021361043A AU2021361043A AU2021361043A1 AU 2021361043 A1 AU2021361043 A1 AU 2021361043A1 AU 2021361043 A AU2021361043 A AU 2021361043A AU 2021361043 A AU2021361043 A AU 2021361043A AU 2021361043 A1 AU2021361043 A1 AU 2021361043A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- certain embodiments
- cancer
- alkyl
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091875P | 2020-10-14 | 2020-10-14 | |
| US63/091,875 | 2020-10-14 | ||
| PCT/US2021/055102 WO2022081925A1 (en) | 2020-10-14 | 2021-10-14 | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021361043A1 true AU2021361043A1 (en) | 2023-06-08 |
| AU2021361043A9 AU2021361043A9 (en) | 2025-03-13 |
Family
ID=81208646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021361043A Pending AU2021361043A1 (en) | 2020-10-14 | 2021-10-14 | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230339902A1 (https=) |
| EP (1) | EP4228639A4 (https=) |
| JP (1) | JP2023545508A (https=) |
| KR (1) | KR20230107569A (https=) |
| CN (1) | CN116783180A (https=) |
| AU (1) | AU2021361043A1 (https=) |
| CA (1) | CA3194169A1 (https=) |
| IL (1) | IL302038A (https=) |
| MX (1) | MX2023004374A (https=) |
| WO (1) | WO2022081925A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN116457339A (zh) * | 2020-10-14 | 2023-07-18 | C4医药公司 | 用于医学治疗的降解新底物的三环化合物 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN118201923A (zh) * | 2021-10-15 | 2024-06-14 | 海南先声再明医药股份有限公司 | 三环类化合物 |
| EP4540241A1 (en) * | 2022-06-16 | 2025-04-23 | Monte Rosa Therapeutics AG | Substituted piperidines as ck1a degraders |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN116655595A (zh) * | 2023-06-05 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 2,6-哌啶二酮衍生物及其制备和用途 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| WO2025006783A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras |
| WO2025097092A1 (en) * | 2023-11-02 | 2025-05-08 | Neomorph, Inc. | Substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and 3-(2-(4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6h-pyrrolo[3,4-b]pyridin-6-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025162410A1 (zh) * | 2024-01-31 | 2025-08-07 | 微境生物医药科技(上海)有限公司 | 新型蛋白降解剂及抗体-蛋白降解剂偶联物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
| CN105985282B (zh) * | 2015-01-28 | 2020-12-08 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用 |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| US11220515B2 (en) * | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| EP3813834B1 (en) * | 2018-06-29 | 2025-03-26 | Dana-Farber Cancer Institute, Inc. | New crbn modulators |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) * | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| KR20210106437A (ko) * | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| EP3924055B1 (en) * | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) * | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CN120172958A (zh) * | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| WO2020243379A1 (en) * | 2019-05-31 | 2020-12-03 | Celgene Corporation | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
| US20240383886A1 (en) * | 2019-12-20 | 2024-11-21 | Calico Life Sciences Llc | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| MX2023001545A (es) * | 2020-08-07 | 2023-05-03 | C4 Therapeutics Inc | Terapias ventajosas para trastornos mediados por ikaros o aiolos. |
| CN116457339A (zh) * | 2020-10-14 | 2023-07-18 | C4医药公司 | 用于医学治疗的降解新底物的三环化合物 |
| EP4228625A4 (en) * | 2020-10-14 | 2026-01-14 | C4 Therapeutics Inc | TRICYCLIC HETEROBFUNCTIONAL COMPOUNDS FOR TARGETED PROTEIN DEGRADATION |
-
2021
- 2021-10-14 IL IL302038A patent/IL302038A/en unknown
- 2021-10-14 CN CN202180083722.6A patent/CN116783180A/zh active Pending
- 2021-10-14 WO PCT/US2021/055102 patent/WO2022081925A1/en not_active Ceased
- 2021-10-14 KR KR1020237015798A patent/KR20230107569A/ko active Pending
- 2021-10-14 EP EP21881142.0A patent/EP4228639A4/en active Pending
- 2021-10-14 MX MX2023004374A patent/MX2023004374A/es unknown
- 2021-10-14 CA CA3194169A patent/CA3194169A1/en active Pending
- 2021-10-14 AU AU2021361043A patent/AU2021361043A1/en active Pending
- 2021-10-14 JP JP2023523007A patent/JP2023545508A/ja active Pending
-
2023
- 2023-04-14 US US18/134,985 patent/US20230339902A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4228639A1 (en) | 2023-08-23 |
| CN116783180A (zh) | 2023-09-19 |
| JP2023545508A (ja) | 2023-10-30 |
| MX2023004374A (es) | 2023-07-06 |
| CA3194169A1 (en) | 2022-04-21 |
| WO2022081925A1 (en) | 2022-04-21 |
| KR20230107569A (ko) | 2023-07-17 |
| AU2021361043A9 (en) | 2025-03-13 |
| US20230339902A1 (en) | 2023-10-26 |
| IL302038A (en) | 2023-06-01 |
| EP4228639A4 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230339902A1 (en) | Tricyclic ligands for degradation of ikzf2 or ikzf4 | |
| JP7846819B2 (ja) | Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬 | |
| US20240018118A1 (en) | Tricyclic compounds to degrade neosubstrates for medical therapy | |
| US12049464B2 (en) | Compounds for targeted degradation of BRD9 | |
| IL302037A (en) | Tricyclic heterobifunctional compounds for degradation of targeted proteins | |
| AU2024306706A1 (en) | Heterobifunctional compounds for the degradation of kras | |
| RU2833608C2 (ru) | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos | |
| JP2025540906A (ja) | Ｒｅｔ－ｌｄｄタンパク質阻害剤 | |
| EA048567B1 (ru) | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |